Novo Nordisk on Tuesday said it will offer its weight loss drug Wegovy through telehealth providers Hims & Hers Health, Ro and LifeMD to expand access to the blockbuster treatment now that it is ...

A bundled offering of Novo Nordisk’s FDA-approved Wegovy® on the Hims & Hers platform marks the first step in a long-term collaboration roadmap, pairing innovative treatments with a leading ...

Novo Nordisk scored a huge legal victory that largely restricts compounding pharmacies from marketing or selling cheaper, unapproved versions of the drugmaker's blockbuster weight loss drug Wegovy ...

Reuters warns that Novo Nordisk's growth rate is slowing. Singapore bank DBS says the stock is a sell. But at 18 times earnings and with a growth rate of 16% or better, Novo Nordisk actually looks ...

Mumbai: Amidst the ongoing news of conventional insulin market disruption and growing concern over potential shortages triggered by Novo Nordisk's decision to withdraw key human insulin products in ...

A housing provider that specialises in offering "high quality" student accommodation has submitted plans to extend a listed building to build an extra flat. Posh Pads has lodged the application ...

LONDON, April 24 (Reuters) - Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk (NOVOb.CO), opens new tab has raised its annual sales guidance several times a year.

Abbott is the marketing partner for Novo’s insulin. Confirming the development, a Novo Nordisk spokesperson said, “In order to meet increasing patient demand and ensure a stable supply of our ...

Are the Ryu and Ken amiibo compatible with SF6? The Smash Bros. Ryu and Ken amiibo appear on Capcom's SF6 amiibo page and do appear to be supported in SF6.

That’s what some are wondering after Novo Nordisk has said it is discontinuing selling its insulin brand in India. The decision from the Danish company could shake up the insulin market, say experts.

Novo Nordisk A/S (NVO) is a high-quality biopharma company that has been a growth play well before its recent obesity drug hit. Shares were hyped a while ago, but have now declined so much that ...

Novo Nordisk (NYSE: NVO), the Danish drugmaker that's been riding high ever since it began putting out Ozempic and Wegovy GLP-1 injectables for treatment of diabetes and weight loss, got another ...